|
[摘要]:Antagonism of the adenosine A(2A) receptor has emerged as a promising non-dopaminergic approach for the potential treatment of Parkinson's disease (PD). Several pharmaceutical and academic institutions have ongoing research programs in this area, and orally efficacious A(2A) receptor antagonists have been advanced into clinical development. Traditionally, antagonists of the A(2A) receptor are classified as xanthine and non-xanthine derivatives. This review provides a detailed summary of the recent SAR development that has led to the discovery of promising non-xanthine-based A(2A) receptor antagonists. The current clinical status and the potential utility of A(2A) receptor antagonists in indications other than PD are also discussed. |
|